Literature DB >> 10411101

Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.

H Noritake1, H Miyamori, C Goto, M Seiki, H Sato.   

Abstract

This article discusses the transformation of epithelial Madin-Durby canine kidney (MDCK) cells with v-src induced expression of membrane-type 1-matrix metalloproteinase (MT1-MMP) and metastatic growth in nude mice (Kadono Y et al., Cancer Res 1998; 58: 2240-44). To analyze genes associated with invasive phenotype of v-src MDCK cells, mRNA differential display was performed between control and the transformed cells. A clone 12', the expression of which was clearly up-regulated in the transformed cells, encoded a protein 81% homologous to human tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). Northern hybridization showed that only MT1-MMP expression was enhanced and other matrix metalloproteinases (MMPs) were undetectable or rather repressed in the transformed cells. Proteolytic activity against type I gelatin was observed in v-src MDCK cells, which was inhibited only by TIMP-2 but not by TIMP-1. MDCK cells stably transfected with the MT1-MMP gene also degraded gelatin, which was selectively inhibited by TIMP-2. These results suggest that MT1-MMP, the expression of which is induced in v-src MDCK cells, degrades extracellullar matrix by itself rather than through the activation of progelatinase A, which in turn contributes to the metastasis of the transformed cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411101     DOI: 10.1023/a:1006596620406

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  32 in total

1.  Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73.

Authors:  T Smeal; B Binetruy; D Mercola; A Grover-Bardwick; G Heidecker; U R Rapp; M Karin
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

2.  MT1-MMP on the cell surface causes focal degradation of gelatin films.

Authors:  M P d'Ortho; H Stanton; M Butler; S J Atkinson; G Murphy; R M Hembry
Journal:  FEBS Lett       Date:  1998-01-09       Impact factor: 4.124

3.  Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness.

Authors:  Y Kadono; Y Okada; M Namiki; M Seiki; H Sato
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma.

Authors:  P D Brown; R E Bloxidge; N S Stuart; K C Gatter; J Carmichael
Journal:  J Natl Cancer Inst       Date:  1993-04-07       Impact factor: 13.506

5.  Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in madin-darby canine kidney epithelial cells.

Authors:  Y Kadono; K Shibahara; M Namiki; Y Watanabe; M Seiki; H Sato
Journal:  Biochem Biophys Res Commun       Date:  1998-10-29       Impact factor: 3.575

Review 6.  Type IV collagenases in invasive tumors.

Authors:  K Tryggvason; M Höyhtyä; C Pyke
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

8.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

Authors:  H Sato; M Seiki
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

9.  Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells.

Authors:  H Sato; Y Kida; M Mai; Y Endo; T Sasaki; J Tanaka; M Seiki
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis.

Authors:  H Kinoh; H Sato; Y Tsunezuka; T Takino; A Kawashima; Y Okada; M Seiki
Journal:  J Cell Sci       Date:  1996-05       Impact factor: 5.285

View more
  7 in total

Review 1.  Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.

Authors:  Ami Patel; Harika Sabbineni; Andrea Clarke; Payaningal R Somanath
Journal:  Life Sci       Date:  2016-05-28       Impact factor: 5.037

2.  Expression of metastasis-associated mts1 gene is co-induced with membrane type-1 matrix metalloproteinase (MT1-MMP) during oncogenic transformation and tubular formation of Madin Darby canine kidney (MDCK) epithelial cells.

Authors:  H Miyamori; K Hasegawa; K R Kim; H Sato
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells.

Authors:  Luis Castro-Sanchez; Adriana Soto-Guzman; Margarita Guaderrama-Diaz; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

Review 4.  Current status of SRC inhibitors in solid tumor malignancies.

Authors:  Lauren N Puls; Matthew Eadens; Wells Messersmith
Journal:  Oncologist       Date:  2011-04-26

Review 5.  Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

Authors:  John de Groot; Vanessa Milano
Journal:  J Neurooncol       Date:  2009-05-13       Impact factor: 4.130

6.  Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.

Authors:  Jeffrey D Bjorge; Andy S Pang; Melanie Funnell; Ke Yun Chen; Roman Diaz; Anthony M Magliocco; Donald J Fujita
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

7.  Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.

Authors:  G R Wilson; A Cramer; A Welman; F Knox; R Swindell; H Kawakatsu; R B Clarke; C Dive; N J Bundred
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.